Join Us for the 2014 Empathic Therapy Conferences

Sign up now to attend our upcoming Empathic Therapy Conference  February 27,28, March 1st, 2014 in Safety Harbor, Florida.  Join Peter Breggin, MD, film maker Kevin Miller, the Florida Adlerian Society and many more speakers. Empathic Therapy, Toxic Psychiatry, Families, Children, Dementia, Recovery, Well-Being,  Addiction, SSRI Violence, Tardive Dyskinesia ~ CEUs available

A Project of the Empathic Therapy Center

ToxicPsychiatry.org is an online library and newspaper project of the 501c3 nonprofit Center for the Study of Empathic Therapy, Education & Living, founded by Peter R. Breggin, MD and Ginger Breggin, working toward replacing the biological theories, diagnoses and treatments of "modern" psychiatry with better therapeutic and educational approaches

Peter R. Breggin, MD Websites
Twitter Feed

Antipsychotic Drugs and Atypical Antipsychotic Drugs

also called neuroleptics

Neuroleptic or antipsychotic drugs disrupt frontal lobe function, causing a chemical lobotomy with apathy and indifference, making emotionally distressed people more submissive and less able to feel. 

 

Long-term Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-Episode Schizophrenia
Beng-Choon Ho, MRCPsych; Nancy C. Andreasen, MD, PhD; etal Arch Gen Psychiatry. 2011;68(2):128-137

     Viewed together with data from animal studies, our study suggests that antipsychotics have a subtle but measurable influence on brain tissue loss over time, suggesting the importance of careful risk-benefit
review of dosage and duration of treatment as well as their off-label use.

 

Changes in Cortical Thickness During the Course of Illness in Schizophrenia
van Haren, N etal, Arch Gen Psychiatry. 2011;68(9):871-880

     In schizophrenia, the cortex shows excessive thinning over time in widespread areas of the brain, most pronounced in the frontal and temporal areas, and progresses across the entire course of the illness. The excessive thinning of the cortex appears related to outcome and medication intake.

 

"Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings" Navari S., and Dazzan P., Psychological Medicine (2009) 39, 1763-1777

     Conclusions: Antipsychotic treatment potentially contributes to the brain structural changes observed in psychosis. Future research should take into account these potential effects, and use adequate sample sizes, to allow improved interpretation of neuroimaging findings in these disorders.

 

Intoxication Anosognosia (Medication Spellbinding)

"Intoxication Anosognosia: The Spellbinding Effect of Psychiatric Drugs", Ethical Human Psychology and Psychiatry, 8, 201-215, 2006.

     ABSTRACT: Why do so many individuals persist in taking psychoactive substances, including psychiatric drugs, after adverse mental and behavioral effects have become severe and even disabling? The author has previously proposed the brain-disabling principle of psychiatric treatment that all somatic psychiatric treatments impair the function of the brain and mind. Intoxication anosognosia (medication spellbinding) is an expression of this druginduced mental disability. Intoxication anosognosia causes the victim to underestimate the degree of drug-induced mental impairment, to deny the harmful role that the drug plays in the person’s altered state, and in many cases compel the individual to mistakenly believe that he or she is functioning better. In the extreme, the individual displays out-of-character compulsively destructive behaviors, including violence toward self and others

 

"A Conversation With Nancy C. Andreasen: Using Imaging to Look at Changes in the Brain" The New York Times, By CLAUDIA DREIFUS, Published: September 15, 2008

"the more drugs you’ve been given, the more brain tissue you lose." Dr. Nancy Andreasen

 

Progressive Brain Changes in Children and Adolescents With First-Episode Psychosis, Celso Arango, MD,et al. Arch Gen Psychiatry 2012 69 (1): 16-26

"Some of the progressive brain changes could be secondary to antipsychotic exposure"

 


Life expectancy and cardiovascular mortality in persons with schizophrenia.
Laursen TM, Munk-Olsen T, Vestergaard M., Curr Opin Psychiatry. 2012 Mar;25(2):83-8.

Abstract
PURPOSE OF REVIEW:

To assess the impact of cardiovascular disease on the excess mortality and shortened life expectancy in schizophrenic patients.
RECENT FINDINGS:

Patients with schizophrenia have two-fold to three-fold higher mortality rates compared with the general population, corresponding to a 10-25-year reduction in life expectancy. Although the mortality rate from suicide is high, natural causes of death account for a greater part of the reduction in life expectancy. The reviewed studies suggest four main reasons for the excess mortality and reduced life expectancy. First, persons with schizophrenia tend to have suboptimal lifestyles including unhealthy diets, excessive smoking and alcohol use, and lack of exercise. Second, antipsychotic drugs may have adverse effects. Third, physical illnesses in persons with schizophrenia are common, but diagnosed late and treated insufficiently. Lastly, the risk of suicide and accidents among schizophrenic patients is high.
SUMMARY:

Schizophrenia is associated with a substantially higher mortality and curtailed life expectancy partly caused by modifiable risk factors.

 

"Antipsychotics: is it time to introduce patient choice?" Anthony P. Morrison, et al, British Journal of Psychiatry, 2012 201:83-84.

Summary: Evidence regarding overestimation of the efficacy of antipsychotics and underestimation of their toxicity, as well as emerging data regarding alternative treatment options, suggests it may be time to introduce patient choice and reconsider whether everyone who meets the criteria for a schizophrenia spectrum diagnosis requires antipsychotics in order to recover.  Read more here.